Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • CF

    - PMLiVE

    Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes

    Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

    - PMLiVE

    Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

    A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

    - PMLiVE

    Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

    Amended agreement sees Vertex take control of gene therapy programme

    - PMLiVE

    Vertex gains FDA fast track designation for diabetes stem cell therapy

    Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

    - PMLiVE

    Moderna inks R&D agreements with Vertex and Chiesi

    Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

    - PMLiVE

    Vertex’s triple combination CF therapy to become available on the NHS

    The drug will immediately become available to thousands of cystic fibrosis patients

    - PMLiVE

    CRISPR gene-editing in cancer patients is safe, according to new study

    Patients had no side effects following CRISPR treatment

    - PMLiVE

    Vertex continues upward trajectory with French Orkambi deal

    Comes on the heels of similar reimbursement deal in England

    - PMLiVE

    Vertex reveals promising data from first CRISPR-treated patients

    Investigational gene therapy has potentially curative effect

    - PMLiVE

    Vertex, NHS England and NICE finally reach agreement for Orkambi

    Deal also includes Vertex’s other licensed cystic fibrosis medicines

    - PMLiVE

    Vertex scores FDA approval for CF triple therapy Trikafta

    Decision comes only a few months after therapy was filed

    - PMLiVE

    Labour Party takes aim at pharma, calls attention to Orkambi row

    Proposal to introduce compulsory licensing faces industry criticism

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links